SETTLEMENT EVALUATIONS ARE CURRENTLY UNDERWAY FOR YAZ, YASMIN, AND OCELLA CASES
JUNE 2011 UPDATE YAZ, YASMIN, AND OCELLA LITIGATION
Last September, 18-year-old Michelle Pfleger collapsed on the way to class at her college. The emergency team rushed Michelle to a nearby hospital. Despite their efforts, they were unable to save Michelle. In May 2011, Joan Cummins, Michelle’s mother, filed a lawsuit against Bayer charging that its birth control drug Yaz caused the blood clot that killed Michelle.
While all birth control pills pose a risk of blood clots, new studies published in April 2011 found that the risk of blood clots for women who used birth control pills containing drospirenone, which include Yaz, Yasmin, Beyaz, Safryl, Ocella, and Gianvi, was two to three times higher than for women taking birth control pills containing levonorgestrel, which is found in earlier generation oral contraceptives.
Last week, the CBS Early Show aired an interview of Ms. Cummins as part of a story on the safety of Yaz. Two days earlier, the FDA announced that it is evaluating the risk of blood clots in women who use birth control pills that contain drospirenone. The FDA’s announcement came soon after the European Medicines Agency stated that it is updating the product information on oral contraceptives with drospirenone on the risk of blood clots.